My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Result Updates | Feb 22nd 2017

Ipca Laboratories Ltd

CMP : 544Target Price : 613

IPCA Labs posted results lower than expected for 3QFY2017 on both sales and net profit fronts, however OPM’s were in-line with expectations. In sales, the company posted sales of Rs731cr, a yoy growth of 8.3% v/s Rs815cr expected. On EBITDA front, the company posted EBITDA of 13.9% (v/s 13.5% expected) v/s 11.6% in 3QFY2016. Consequently,..

View As PDF

Result Updates | Feb 22nd 2017

Dr Reddys Laboratories Ltd

CMP : 2,899Target Price :

Dr. Reddy’s Laboratories (DRL) posted lower than expected results for 3QFY2017. In INR terms, the consolidated revenues came in at Rs3,707cr (v/s. Rs4,000cr expected) v/s. Rs3,989cr in 3QFY2016, down 6.6% yoy, mainly driven by pressure on the generic market. The global generic market with sales at Rs3,064cr (down 9.0% yoy), was mainly lea..

View As PDF

Sort By

Result Updates | Feb 16th 2017

Garware-Wall Ropes Ltd

CMP : 614
Target Price : 710

For 3QFY2017 Garware Wall Ropes (GWRL) posted results which outperformed our estimates on the bottom-line front, while the top-line was in-line with our estimates. On the operating front, the company reported margin improvement, primarily on account of lower other expenditures. Further, on the bottom-line front, the company reported stron..

Result Updates | Feb 15th 2017

Glaxosmithkline Pharma Ltd

CMP : 2,683
Target Price :

For 3QFY2017 Glaxo Pharmaceuticals (GSK) posted results lower than expectations on all fronts. In sales, the company posted sales of Rs689cr v/s Rs700cr expected, a yoy de-growth of 5.6%. On EBITDA front, the company posted EBITDA of 5.1% (v/s 9.1% expected) v/s 11.6% in 3QFY2016. Consequently, Adj. PAT came in at Rs40.8cr (v/s Rs78.4cr e..

Result Updates | Feb 15th 2017

Sun Pharmaceuticals Industries Ltd

CMP : 650
Target Price : 847

For 3QFY2017 Sun Pharmaceuticals posted results marginally lower than expectations on sales front, while OPM came in much below expectation, however, net profit was slightly below expectations. Sales came in at Rs7,683cr (v/s Rs7800cr expected) v/s Rs7,087cr in 3QFY2016, a yoy growth of 8.4%. Indian sales at Rs1,969cr, posted a yoy growth..

Result Updates | Feb 15th 2017

Bank of Baroda

CMP : 168
Target Price :

BoB’s 3QFY17 results remained disappointing. The bank continues to face headwinds on asset quality on one hand, while on the other hand the balance sheet continued to de-grow as the management intentionally downsized some low margin business. Coming few quarters might be challenging for the bank. With continued pressure on asset quality a..

Result Updates | Feb 14th 2017

Hero MotoCorp Ltd

CMP : 3,226
Target Price : 3,466

The demonetisation has impacted HMCL’s volumes sharply with decline in all parameters. Company expects the volumes growth to remain challenging in 4QFY17E and expects high single digit volume growth in FY18E. As automobile industry recovers, HMCL looks to be better positioned due to its higher market share in the motorcycle segment. The c..

Result Updates | Feb 14th 2017

Hero MotoCorp Ltd

CMP : 3,226
Target Price : 3,466

The demonetisation has impacted HMCL’s volumes sharply with decline in all parameters. Company expects the volumes growth to remain challenging in 4QFY17E and expects high single digit volume growth in FY18E. As automobile industry recovers, HMCL looks to be better positioned due to its higher market share in the motorcycle segment. The c..

Result Updates | Feb 14th 2017

Cipla Ltd

CMP : 581
Target Price : 465

Cipla posted numbers lower than expected for 3QFY2017. The company reported sales of Rs3,550cr v/s Rs3,737cr expected, registering a yoy growth of 15.6%, mainly aided by domestic formulations. Domestic at Rs1,408cr registered a yoy growth of 19.1%, while exports at Rs2,239cr posted yoy growth of 13.7%. On operating front, the EBITDA margi..

Result Updates | Feb 14th 2017

Lupin Ltd

CMP : 1,448
Target Price : 1,809

For 3QFY2017 Lupin posted results much better than expected on sales and OPM fronts. In sales, the company posted sales of Rs4,110cr v/s Rs4,000cr expected yoy growth of 31.3%. The strong sales growth was aided by the USA (contributed around 49.0%), which registered a yoy growth of 57.6%. On EBITDA front, the company posted EBITDA of 25.9..

Result Updates | Feb 14th 2017

Alkem Laboratories Ltd

CMP : 1,837
Target Price : 1,996

The stock at the CMP of Rs1,837 is available at P/E of 17.5x of FY19E EPS of `105. The stock price in CY2017 has appreciated by 13% leaving less room for further upside at this juncture. We expect company to report CAGR of 17.4% and 22.4% in top line and bottom line respectively in next two years. Its ANDA pipeline has not seen strong tra..

Result Updates | Feb 13th 2017

Radico Khaitan Ltd

CMP : 128
Target Price : 147

Radico Khaitan’s (RKL) results for 3QFY2017 were below our estimates both on top-line as well as bottom-line fronts. The company’s top-line grew by ~4% yoy to `415cr owing to the impact of demonetization, which led to a decline in consumer spending. Moreover, lower sales volume and subdued operating performance led to the de-growth in bot..